Volume 8, Issue 1, March 2020, Page: 1-7
Mutation of EGFR in Non-small Cell Lung Cancer, a Regional Study in Upper Egypt
Samir Shehata Mohammed Eid, Department of Clinical Oncology, Assiut University, Assiut, Egypt
Ahmed Roshdi Hamed Ahmed, Department of Pathology, Sohag University, Sohag, Egypt
Marwa Ismail Khalaf Abdelgawad, Department of Clinical Oncology, Assiut University, Assiut, Egypt
Ahmed El-Sayed Mohamed, Department of Clinical and Radiation Oncology, Sohag University, Sohag, Egypt
Amany Osama Mohamed, Department of Medical Biochemistry, Assiut University, Assiut, Egypt
Dalia Osama Mohamed, Department of Radiation Oncology, South Egypt Cancer Institute, Assiut, Egypt
Mona Mahmoud Sayed, Department of Radiation Oncology, South Egypt Cancer Institute, Assiut, Egypt
Ebtesam Mahmoud Aly Elgezawy, Department of Clinical Pathology, Assiut University, Assiut, Egypt
Heba Mohammed Saad-Eldeen, Department of Histology, Tissue Culture and Molecular Biology, Assiut University, Assiut, Egypt
Received: Dec. 2, 2019;       Accepted: Dec. 26, 2019;       Published: Jan. 7, 2020
DOI: 10.11648/j.crj.20200801.11      View  17      Downloads  16
Abstract
Management of non-small cell lung cancer has been changed dramatically since detection of EGFR mutation. The rate of EGFR mutation in Upper Egypt is unknown. In this study; EGFR mutation in non-small cell lung cancer tissue was evaluated and correlated with clinicopathological features of the tumors. Tissue samples of non-small cell lung cancer that had been confirmed by histopathological and immunohistochemical examinations were evaluated for mutation of EGFR by StripAssay. Thirty four patients with non-small cell lung cancer; 21 males and 13 females with a mean age of 55.94 years were included in this study. The median tumor size was 6.0cm and more than half of the tumors were classified as T3. Fourteen patients had N2 nodal stage and 19 patients had either malignant pleural effusion or distant metastasis. The majority of the tumors were adenocarcinomas and half of them were grade II. The two year survival rate of the patients was 70.6% and the overall survival was 58.8%. EGFR mutation was recorded in 44.1% of the tumors; all of which were adenocarcinoma variant. The mutation was significantly more frequent in large sized tumors and it was relatively associated with poor survival. Mutation of EGFR was not associated with patients` age, sex, tumor grade, T stage, N stage or status of distant metastasis. The rate of EGFR gene mutation in non-small cell lung cancer in Upper Egypt is relatively high and target therapy based on these mutations could improve patients` outcome.
Keywords
NSCLC, EGFR Mutation, Adenocarcinoma, Tumor Size
To cite this article
Samir Shehata Mohammed Eid, Ahmed Roshdi Hamed Ahmed, Marwa Ismail Khalaf Abdelgawad, Ahmed El-Sayed Mohamed, Amany Osama Mohamed, Dalia Osama Mohamed, Mona Mahmoud Sayed, Ebtesam Mahmoud Aly Elgezawy, Heba Mohammed Saad-Eldeen, Mutation of EGFR in Non-small Cell Lung Cancer, a Regional Study in Upper Egypt, Cancer Research Journal. Vol. 8, No. 1, 2020, pp. 1-7. doi: 10.11648/j.crj.20200801.11
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract. 2012; 2012: 817297. doi: 10.1155/2012/817297.
[2]
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014; 2014: 437971. doi: 10.1155/2014/437971.
[3]
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006; 33 (4): 369-85.
[4]
Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10 (12Pt2): 4227s-32s.
[5]
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350 (21): 2129-39.
[6]
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304 (5676): 1497-500.
[7]
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361 (10): 947-57.
[8]
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13 (3): 239-46.
[9]
Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27 (9): 1394-400.
[10]
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362 (25): 2380-88.
[11]
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013; 137 (6): 828-60.
[12]
Haaland B, Tan PS, de Castro G, Jr., Lopes G. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014; 9 (6): 805-11.
[13]
Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, et al. Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med. 2018; 142 (2): 163-167.
[14]
Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9 (2): 154-62.
[15]
Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011; 73 (3): 316-19.
[16]
Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One. 2013, 8 (10): e76164.
[17]
Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008; 99 (11): 1757-62.
[18]
Veldore VH, Rao RM, Kakara S, Pattanayak S, Tejaswi R, Sahoo R, et al. Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer. 2013; 50 (2): 87-93.
[19]
Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS One. 2016; 11 (6): e0156728.
[20]
Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res. 2005; 11 (19Pt1): 6816-22.
[21]
Wang H, Zhang W, Wang K, Li X. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma. Medicine (Baltimore). 2018; 97 (26): e11116.
[22]
Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol. 2010, 5 (12): 1949-52.
[23]
Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016; 102: 122-34.
[24]
Miyamae Y, Shimizu K, Hirato J, Araki T, Tanaka K, Ogawa H, et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011, 25 (4): 921-28.
[25]
Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012; 18 (9): 2443-51.
[26]
Wang K, Gong H, Li X, Yang Z, Cao P, Wand C, et al. Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma. Zhonghua Bing Li Xue Za Zhi. 2015; 44 (3): 170-4.
[27]
Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G. EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients. Cancer Manag Res. 2019; 11: 1945-57.
[28]
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11 (2): 121-8.
Browse journals by subject